A single-center, open-label, single-arm trial to evaluate the efficacy and safety of cidofovir IV therapy combined with oral probenecid for patients with mpox or smallpox.

Morioka Shinichiro0 个研究点目标入组 20 人开始时间: 2024年2月22日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•In case of smallpox, the patient must satisfy 1) to 3) and 6). In the case of Mpox, all of 1) to 6) must be met.
•1) Individuals who have given written consent to participate in research.
•2) Persons who are between the ages of 18 and 60 at the time of consent.
•3) Individuals who have been diagnosed with mpox or smallpox. However, smallpox is diagnosed when the agent is detected in a blister, pustule, crust, throat swab, or blood sample, and mpox is diagnosed when the agent is detected in a skin or mucosal lesion, blister contents, nasopharyngeal swab, or blood sample, nasopharyngeal swab, pharyngeal swab, anorectal swab, other mucosal swab, blood, urine, or other material appropriate to the test method, by any of the following methods.
•Direct observation of viral particles by electron microscopy
•Detection of pathogens by isolation and identification
•Detection of pathogen antigens by the fluorescent antibody method
•Detection of pathogen genes by PCR
•4) Persons participating in the Multicenter, Open Label, Two Arm, Multicenter Study to Evaluate the Efficacy and Safety of Oral Tecovirimat Treatment for mpox and Smallpox (hereafter referred to as the Tecopox Study) Certification No CRB3200011 and who are treated with tecovirimat.
•5) Patients with severe mpox or severe high risk mpox.
•6) Patients who agree to be hospitalized and treated with cidofovir for up to 30 days after initiation of treatment with cidofovir.

•1) Patients with renal insufficiency (serum creatinine level > 1.5 mg/dl, creatinine clearance <= 55 ml/min), proteinuria (urine protein = > 100 mg/dl, urine protein qualitative = > 2+).
•(2) Patients who are receiving or have received within 7 days drugs with potential nephrotoxicity (drugs with potential nephrotoxicity: aminoglycoside injection (tobramycin, gentamicin, amikacin, etc.), amphotericin B, foscarnet, pentamidine injection, vancomycin, non-steroidal anti-inflammatory drugs, etc.).
•3) Patients who are receiving or have received brincidofovir within 7 days.
•4) Patients with a history of hypersensitivity to cidofovir
•5) Patients who have had hypersensitivity reactions to probenecid.
•6) Patients with allergy to sulfa drugs
•7) Patients with kidney stone disease
•8) Patients with blood disorders
•9) Pregnant women
•10) Nursing patients
•11) Patients deemed inappropriate for inclusion in the study by the investigator

发起方

Morioka Shinichiro